TY  - RPRT
TI  - Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell
AU  - Hu, Y.
AU  - Jo, H.
AU  - DeGrado, W.
AU  - Wang, J.
PY  - 2021
DO  - 10.1101/2021.11.04.467344
UR  - https://www.biorxiv.org/content/10.1101/2021.11.04.467344v1
ID  - 10.1101/2021.11.04.467344
ER  -